Announcements Trials
Browse Landscape

Status

Terminated 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Thoracic 2Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms by Site 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Patient Reported Outcome Measures × Thoracic × Clear all
NCT03053297 2018-02-08

PANORAMA

AstraZeneca

Terminated
89 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02405247 2015-07-31

TAURAS

AstraZeneca

Terminated
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡